How many clinical trials are studying Fludrocortisone acetate?

3 recruiting trials in our tracked data involve Fludrocortisone acetate.

What conditions is Fludrocortisone acetate being studied for?

In our tracked recruiting trials, Fludrocortisone acetate is being studied in trials for Prostate cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer Metastatic.

Fludrocortisone acetate: clinical trials recruiting now

Q: Is Fludrocortisone acetate FDA-approved?

Yes. According to the FDA drug label available through openFDA, Fludrocortisone acetate is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Fludrocortisone acetate appears in the FDA drug-label database. Marketed as Fludrocortisone Acetate.

FDA-approved use

Fludrocortisone acetate tablets, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 2 1 Phase 3 2

Conditions being studied

Condition	Trials
Prostate cancer · Fludrocortisone acetate for Prostate cancer	3
Metastatic Castration-resistant Prostate Cancer (mCRPC)	1
Prostate Cancer Metastatic	1
Prostatic Neoplasms	1
Prostatic Neoplasms, Castration-Resistant	1

Recruiting trials involving Fludrocortisone acetate

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 330 locations
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 288 locations
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 77 locations

Common questions

Is Fludrocortisone acetate FDA-approved?

Yes, marketed as Fludrocortisone Acetate.

How many recruiting trials involve Fludrocortisone acetate?

3 recruiting trials across 5 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.